(GYRE) Gyre Therapeutics, Inc. Business Model Canvas Research

Gyre Therapeutics, Inc. depends on contract manufacturers for API and finished-dose supply, since small-molecule drugs need consistent quality, batch release, and scale-up from clinical to commercial volumes. This matters most for ETUARY and pipeline assets, where reliable partners reduce supply risk and help keep development moving.

• API supply must stay stable
• Finished-dose scale-up is critical
• Supports ETUARY and pipeline

Drug approval and reimbursement hinge on 2 gatekeepers: regulators and payer systems. For anti-fibrotic therapies, specialty hospitals and clinics drive uptake because they concentrate the right patients and influence referral flow.

Gyre Therapeutics, Inc.’s access path depends on these 3 partner groups shaping approval, coverage, and real-world use.

• Regulators set approval.
• Payers set coverage.
• Specialty centers drive adoption.

Gyre Therapeutics, Inc. depends on GMP manufacturing, batch release, stability testing, and distribution planning so its commercial products and clinical candidates meet quality standards. Supply continuity matters because any raw-material or release delay can hit both trial dosing and market demand.

• Quality starts with raw materials
• Batch release protects product integrity
• Stability data supports shelf life
• Planning keeps trials supplied

Gyre Therapeutics, Inc. must educate specialists, back adoption, and run evidence, safety, and market-access work in parallel; that gets more important as approved and late-stage assets grow. Launch execution is where clinical data turns into paid use.

• Train specialists early
• Generate post-launch evidence
• Monitor safety closely
• Plan payer access upfront

Gyre Therapeutics, Inc.’s scientific and development team is a core asset because it must cover pharmacology, clinical operations, regulatory affairs, and CMC (chemistry, manufacturing, and controls) across multi-indication programs. In biotech, human capital is the main engine of speed and compliance, so the right specialists can cut delay risk and protect pipeline value.

• Pharmacology, clinical, regulatory, CMC
• Critical for complex multi-indication work

Gyre Therapeutics, Inc. is headquartered in San Diego, California, which gives it a U.S. operating base for coordination, hiring, and day-to-day execution. Its status as a subsidiary of GNI USA, Inc. adds governance support and capital backing, helping align development work and corporate oversight.

• San Diego base supports U.S. operations.
• GNI USA backing strengthens governance.
• Subsidiary structure aids execution discipline.

Gyre Therapeutics, Inc. builds on a small-molecule development platform, not biologics. Small molecules can be taken by mouth and are usually easier and cheaper to make, which helps move one core chemistry engine across multiple disease areas.

• Oral dosing can improve convenience.
• Manufacturing is often simpler.
• One platform can serve many indications.

Gyre Therapeutics, Inc. has a pipeline that spans Phase 1, Phase 2, Phase 3, and preclinical assets, so value does not hinge on one drug. That gives it multiple shots on goal and lowers binary risk versus a single-asset model; in 2025, the company reported a multi-stage portfolio built around fibrosis and inflammation programs.

• Phase 1 to preclinical spread
• Less single-asset dependence
• More paths to future value

Gyre Therapeutics, Inc. uses medical affairs to explain anti-fibrotic data in plain clinical terms: trial endpoints, safety, and who should use each therapy. That matters because 2025 filings show R&D stayed a major cash use, so trusted, evidence-based talks help convert complex science into physician confidence.

• Share trial and safety data
• Clarify appropriate use
• Build HCP credibility

ETUARY needs continuous pharmacovigilance, meaning Gyre Therapeutics, Inc. keeps collecting and reviewing adverse-event reports after launch. That follow-up helps physicians see the drug is being monitored and gives regulators a clear safety trail, so the customer relationship stays active well beyond approval.

• Track adverse events after launch
• Share follow-up with regulators
• Build prescriber trust over time

Reimbursement is a key gate for Gyre Therapeutics, Inc. chronic specialty medicines: U.S. specialty drugs were about 75% of drug spend but only 6% of prescriptions in 2025, so access rules matter more than price alone. Health plans, hospital formularies, and pharmacy benefit managers shape step edits, prior auth, and real-world uptake.

• Health plans can delay starts.
• Hospital formularies drive inpatient use.
• Pharmacy benefits shape refill access.

Gyre Therapeutics, Inc. uses specialty pharmacy and controlled distribution for approved fibrosis therapies, which supports patient start-up, refill follow-up, safety checks, and utilization tracking. Public 2025/2026 channel-level prescription or shipment metrics were not disclosed in the latest filings I could verify, so this channel should be treated as a monitored access point, not a broad retail route.

• Controlled access supports onboarding
• Refills improve persistence tracking
• Safety coordination stays centralized
• Utilization data can be monitored

Gyre Therapeutics, Inc. targets chronic hepatitis B-induced liver fibrosis and NASH fibrosis patients, a large specialty-care pool managed mainly by hepatologists and gastroenterologists. Global chronic hepatitis B affects about 254 million people, and MASH/NASH is common in the 20%-30% of adults with fatty liver, making fibrosis a high-value market for F351 in Phase 3 for hepatitis B-related fibrosis and Phase 1 for NASH fibrosis.

• Specialists drive diagnosis and treatment
• HBV fibrosis has a 254 million-patient base
• NASH fibrosis has broad unmet demand
• Fibrosis is the key commercial wedge

Hospitals, specialty physicians, and payers are the buying and access gatekeepers for Gyre Therapeutics, Inc.; hospitals shape protocol use, specialty doctors drive adoption, and payers decide reimbursement and formulary access. In the U.S., Medicare covered about 68 million people in 2025, so payer approval can make or break commercial uptake.

• Hospitals influence use in care pathways.
• Specialists drive prescribing and adoption.
• Payers set reimbursement and access.
• Formulary placement supports sales scale.

Regulatory and compliance costs are non-discretionary for Gyre Therapeutics, Inc.: approvals, filings, inspections, and safety reporting add fixed overhead, and a firm with one approved product plus multiple trials still carries ongoing FDA and ethics-review work. In FY2026, FDA application fees alone can run into millions of dollars, before routine monitoring and reporting.

• Non-discretionary compliance spend
• Multi-trial safety reporting burden
• High fixed FDA filing overhead

That means cost pressure stays even when revenue is still narrow.

General and administrative expenses cover Gyre Therapeutics, Inc.’s corporate operations, legal, finance, and executive work, so they act as fixed overhead for the business. As a San Diego-based subsidiary, Gyre also needs governance, compliance, and reporting systems that keep enterprise operations running and support public-company discipline.

• Corporate overhead: legal, finance, executive
• Supports governance and reporting
• Needed for subsidiary-level control

F573 is in Phase 2 for acute and acute-on-chronic liver failure, so any positive data could open a new specialty-liver revenue stream for Gyre Therapeutics, Inc. Acute liver failure is rare but severe, with U.S. incidence often cited around 2,000 cases a year and mortality still high without transplant, so even a small approved niche could add a distinct, high-value product line and reduce reliance on current mix.

• Phase 2 asset with niche upside
• Rare disease, high unmet need
• Could diversify future revenue mix

F528 and F230 are preclinical programs for COPD and PAH, so they are not near-term revenue streams for Gyre Therapeutics, Inc. Their monetization is back-ended: value only emerges if they clear clinical testing and win regulatory approval, a process that is risky and capital intensive.

• Preclinical, not current sales drivers
• Targets COPD and PAH
• Future value hinges on approval
• Success could create licensing or product revenue